-

Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general public via webcast.

Webcast Information

To access the live webcast of Quanterix’s fireside chat presentation at the conference, please visit this link.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of the company’s website.

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Contacts

Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

Quanterix Corporation

NASDAQ:QTRX

Release Versions

Contacts

Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

Social Media Profiles
More News From Quanterix Corporation

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements to correct non-cash errors related to those periods. “Quanterix continues to build on our strong momentum, achieving...

Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results. Quanterix will issue a press release regarding third quarter 2024 financial results prior to the conference call on Tuesday, November 12, 2024, after the market closes. The press release will...

New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range of patients. Recent Alzheimer’s Association criteria for diagnosing Alzheimer’s recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this app...
Back to Newsroom